retatrutide phase 2 trial obesity nejm 2023 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor Agonist for — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Incretin triple agonist retatrutide (LY3437943)

Boost Synergy GLP-1 For readers comparing a GLP-1 probiotic supplement , Boost Synergy GLP-1 is best understood as a microbiome-targeted formula that may support SCFA pathways, GLP-1 physiology, gut microbial balance, and metabolic signaling alongside diet, lifestyle, and circadian repair

Advances in the field of weight loss drugs are evolving rapidly

This pattern makes it easy to verify your calculation mentally

Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire

Growth opportunities found in ingredients which manage blood sugar and treat GLP-1 symptoms As GLP-1 drugs become more widespread, a new wave of products is emerging to manage common side effects

Using a pen that delivers 1 mg or 2 mg doses when prescribed 0.25 mg or 0.5 mg results in significant overdosing